FAQ/Help |
Calendar |
Search |
Today's Posts |
07-12-2016, 12:39 PM | #1 | ||
|
|||
Member
|
This is great news folks!
Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s Posted by Maggie McGuire Kuhl, July 12, 2016 A promising therapy that may slow or stop Parkinson’s progression is moving forward. Today The Michael J. Fox Foundation (MJFF), the Van Andel Research Institute (VARI) in Michigan and the Cure Parkinson’s Trust (CPT) in the United Kingdom announced plans to collaborate to assess the clinical use and development of cancer drug nilotinib. The program includes the goal of planning of a double-blind, placebo-controlled clinical trial of nilotinib, which MJFF hopes can begin in 2017. Parkinson's Disease | Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s Last edited by zanpar321; 07-12-2016 at 02:39 PM. Reason: Adding new text |
||
Reply With Quote |
07-12-2016, 04:26 PM | #2 | ||
|
|||
Member
|
Yes, zanpar, this is really good news. It took some time, and some pressure, but we've finally gotten the big guns to realize that this study needed to get done. The science makes sense, the pre-clinical trials have all been successful, the recent research on c-abl and TKIs, and the Georgetown proof-of-concept trial all support the need for further investigation of Nilotinib in a controlled clinical trial.
Coincidentally, the Georgetown study results were finally published today. See my post on that thread for the publication link. |
||
Reply With Quote |
"Thanks for this!" says: | Betsy859 (07-17-2016), jeffreyn (07-12-2016), RLSmi (07-12-2016), soccertese (07-14-2016), zanpar321 (07-12-2016) |
07-12-2016, 04:31 PM | #3 | ||
|
|||
Member
|
Also, the team at Georgetown still intends to conduct their own Nilotinib phase 2 trials. It will probably begin before the MJFF study and both will be conducted simultaneously.
|
||
Reply With Quote |
07-13-2016, 10:28 AM | #4 | ||
|
|||
Member
|
"Our hope is to clarify the benefits of nilotinib to patients in a much larger and well controlled study. This was a very promising start," Moussa says. "If these data hold out in further studies, nilotinib would be the most important treatment for Parkinsonism since the discovery of Levodopa almost 50 years ago."
https://www.sciencedaily.com/release...0712101230.htm Last edited by zanpar321; 07-14-2016 at 08:07 AM. Reason: wrong link |
||
Reply With Quote |
07-14-2016, 08:51 AM | #5 | ||
|
|||
Member
|
|
||
Reply With Quote |
07-14-2016, 09:06 AM | #6 | ||
|
|||
Member
|
Quote:
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies - IOS Press |
||
Reply With Quote |
07-14-2016, 12:29 PM | #7 | ||
|
|||
Member
|
|
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Michael J. Fox Foundation Partners with Charles River Laboratories on Parkinson’s Res | Parkinson's Disease | |||
NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development o | Parkinson's Disease | |||
NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development o | Parkinson's Disease | |||
ALS Therapy Development Institute Partners with Clinical Centers to Establish Patholo | ALS News & Research |